Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Several case reports have indicated that the selective serotonin re-uptake inhibitor (SSRI) fluoxetine increases phenytoin blood levels when given concurrently. The mechanism of this drug-drug interaction has been attributed to inhibition of CYP2C9-catalyzed hydroxylation of phenytoin to its major oxidative metabolite in humans, para-hydroxyphenyl phenyl hydantoin (HPPH). With a bank of human liver microsomes (HLM), four SSRIs (fluoxetine, norfluoxetine, sertraline, and paroxetine) were tested for inhibition of HPPH formation. Initially, the Km and Vmax values of phenytoin hydroxylation to HPPH were determined in the individual HLM samples. The average Km (n = 8) was 9.7 ± 2.9 μM. The Vmax varied fivefold, with an average value of 113 ± 53 pmol HPPH/min/nmol CYP450. All of the SSRIs inhibited HPPH formation; resulting Ki values were 31.1 ± 10.1 μM (fluoxetine) (n = 5), 51.1 ± 9.4 μM (norfluoxetine) (n = 3), 52.2 ± 21.5 μM (sertraline) (n = 3), and 80.0 ± 7.2 μM (paroxetine) (n = 3). Sulfaphenazole (10 μM), utilized as a positive control for inhibition of HPPH formation, inhibited phenytoin hydroxylation (> 95%) in all HLM samples. Diclofenac hydroxylation to 4′-OH diclofenac, a specific marker for CYP2C9 activity, was determined in HLM1-HLM6 and was highly correlated with HPPH formation in HLM1-HLM6, indicating that phenytoin hydroxylation in human liver microsomes is largely due to CYP2C9. This work presents direct evidence that the effect of fluoxetine on phenytoin blood levels may be explained by inhibition of CYP2C9-catalyzed phenytoin hydroxylation. In light of typical SSRI blood levels observed in patients, this study also suggests that the risk of a SSRI-phenytoin interaction is highest with fluoxetine and norfluoxetine, and less likely with sertraline and paroxetine.

Original languageEnglish (US)
Pages (from-to)71-82
Number of pages12
JournalEpilepsy Research
Volume44
Issue number1
DOIs
StatePublished - Mar 24 2001

Fingerprint

Hydantoins
Serotonin Uptake Inhibitors
Phenytoin
Liver Microsomes
Hydroxylation
Fluoxetine
Sertraline
Paroxetine
Diclofenac
Sulfaphenazole
Drug Interactions
Cytochrome P-450 CYP2C9

Keywords

  • Anti-epileptic drugs
  • Drug interactions
  • Human liver microsomes
  • Phenytoin
  • Selective serotonin re-uptake inhibitors

Cite this

Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. / Nelson, M. H.; Birnbaum, A. K.; Remmel, R. P.

In: Epilepsy Research, Vol. 44, No. 1, 24.03.2001, p. 71-82.

Research output: Contribution to journalArticle

@article{07df161756964522b9ae9d5189cf5467,
title = "Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors",
abstract = "Several case reports have indicated that the selective serotonin re-uptake inhibitor (SSRI) fluoxetine increases phenytoin blood levels when given concurrently. The mechanism of this drug-drug interaction has been attributed to inhibition of CYP2C9-catalyzed hydroxylation of phenytoin to its major oxidative metabolite in humans, para-hydroxyphenyl phenyl hydantoin (HPPH). With a bank of human liver microsomes (HLM), four SSRIs (fluoxetine, norfluoxetine, sertraline, and paroxetine) were tested for inhibition of HPPH formation. Initially, the Km and Vmax values of phenytoin hydroxylation to HPPH were determined in the individual HLM samples. The average Km (n = 8) was 9.7 ± 2.9 μM. The Vmax varied fivefold, with an average value of 113 ± 53 pmol HPPH/min/nmol CYP450. All of the SSRIs inhibited HPPH formation; resulting Ki values were 31.1 ± 10.1 μM (fluoxetine) (n = 5), 51.1 ± 9.4 μM (norfluoxetine) (n = 3), 52.2 ± 21.5 μM (sertraline) (n = 3), and 80.0 ± 7.2 μM (paroxetine) (n = 3). Sulfaphenazole (10 μM), utilized as a positive control for inhibition of HPPH formation, inhibited phenytoin hydroxylation (> 95{\%}) in all HLM samples. Diclofenac hydroxylation to 4′-OH diclofenac, a specific marker for CYP2C9 activity, was determined in HLM1-HLM6 and was highly correlated with HPPH formation in HLM1-HLM6, indicating that phenytoin hydroxylation in human liver microsomes is largely due to CYP2C9. This work presents direct evidence that the effect of fluoxetine on phenytoin blood levels may be explained by inhibition of CYP2C9-catalyzed phenytoin hydroxylation. In light of typical SSRI blood levels observed in patients, this study also suggests that the risk of a SSRI-phenytoin interaction is highest with fluoxetine and norfluoxetine, and less likely with sertraline and paroxetine.",
keywords = "Anti-epileptic drugs, Drug interactions, Human liver microsomes, Phenytoin, Selective serotonin re-uptake inhibitors",
author = "Nelson, {M. H.} and Birnbaum, {A. K.} and Remmel, {R. P.}",
year = "2001",
month = "3",
day = "24",
doi = "10.1016/S0920-1211(00)00203-5",
language = "English (US)",
volume = "44",
pages = "71--82",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors

AU - Nelson, M. H.

AU - Birnbaum, A. K.

AU - Remmel, R. P.

PY - 2001/3/24

Y1 - 2001/3/24

N2 - Several case reports have indicated that the selective serotonin re-uptake inhibitor (SSRI) fluoxetine increases phenytoin blood levels when given concurrently. The mechanism of this drug-drug interaction has been attributed to inhibition of CYP2C9-catalyzed hydroxylation of phenytoin to its major oxidative metabolite in humans, para-hydroxyphenyl phenyl hydantoin (HPPH). With a bank of human liver microsomes (HLM), four SSRIs (fluoxetine, norfluoxetine, sertraline, and paroxetine) were tested for inhibition of HPPH formation. Initially, the Km and Vmax values of phenytoin hydroxylation to HPPH were determined in the individual HLM samples. The average Km (n = 8) was 9.7 ± 2.9 μM. The Vmax varied fivefold, with an average value of 113 ± 53 pmol HPPH/min/nmol CYP450. All of the SSRIs inhibited HPPH formation; resulting Ki values were 31.1 ± 10.1 μM (fluoxetine) (n = 5), 51.1 ± 9.4 μM (norfluoxetine) (n = 3), 52.2 ± 21.5 μM (sertraline) (n = 3), and 80.0 ± 7.2 μM (paroxetine) (n = 3). Sulfaphenazole (10 μM), utilized as a positive control for inhibition of HPPH formation, inhibited phenytoin hydroxylation (> 95%) in all HLM samples. Diclofenac hydroxylation to 4′-OH diclofenac, a specific marker for CYP2C9 activity, was determined in HLM1-HLM6 and was highly correlated with HPPH formation in HLM1-HLM6, indicating that phenytoin hydroxylation in human liver microsomes is largely due to CYP2C9. This work presents direct evidence that the effect of fluoxetine on phenytoin blood levels may be explained by inhibition of CYP2C9-catalyzed phenytoin hydroxylation. In light of typical SSRI blood levels observed in patients, this study also suggests that the risk of a SSRI-phenytoin interaction is highest with fluoxetine and norfluoxetine, and less likely with sertraline and paroxetine.

AB - Several case reports have indicated that the selective serotonin re-uptake inhibitor (SSRI) fluoxetine increases phenytoin blood levels when given concurrently. The mechanism of this drug-drug interaction has been attributed to inhibition of CYP2C9-catalyzed hydroxylation of phenytoin to its major oxidative metabolite in humans, para-hydroxyphenyl phenyl hydantoin (HPPH). With a bank of human liver microsomes (HLM), four SSRIs (fluoxetine, norfluoxetine, sertraline, and paroxetine) were tested for inhibition of HPPH formation. Initially, the Km and Vmax values of phenytoin hydroxylation to HPPH were determined in the individual HLM samples. The average Km (n = 8) was 9.7 ± 2.9 μM. The Vmax varied fivefold, with an average value of 113 ± 53 pmol HPPH/min/nmol CYP450. All of the SSRIs inhibited HPPH formation; resulting Ki values were 31.1 ± 10.1 μM (fluoxetine) (n = 5), 51.1 ± 9.4 μM (norfluoxetine) (n = 3), 52.2 ± 21.5 μM (sertraline) (n = 3), and 80.0 ± 7.2 μM (paroxetine) (n = 3). Sulfaphenazole (10 μM), utilized as a positive control for inhibition of HPPH formation, inhibited phenytoin hydroxylation (> 95%) in all HLM samples. Diclofenac hydroxylation to 4′-OH diclofenac, a specific marker for CYP2C9 activity, was determined in HLM1-HLM6 and was highly correlated with HPPH formation in HLM1-HLM6, indicating that phenytoin hydroxylation in human liver microsomes is largely due to CYP2C9. This work presents direct evidence that the effect of fluoxetine on phenytoin blood levels may be explained by inhibition of CYP2C9-catalyzed phenytoin hydroxylation. In light of typical SSRI blood levels observed in patients, this study also suggests that the risk of a SSRI-phenytoin interaction is highest with fluoxetine and norfluoxetine, and less likely with sertraline and paroxetine.

KW - Anti-epileptic drugs

KW - Drug interactions

KW - Human liver microsomes

KW - Phenytoin

KW - Selective serotonin re-uptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0035095338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035095338&partnerID=8YFLogxK

U2 - 10.1016/S0920-1211(00)00203-5

DO - 10.1016/S0920-1211(00)00203-5

M3 - Article

C2 - 11255075

AN - SCOPUS:0035095338

VL - 44

SP - 71

EP - 82

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 1

ER -